MCC950 is an inhibitor of NOD-like receptor protein 3 (NLRP3) inflammasome activation. It inhibits ATP-induced IL-1β release in LPS-primed mouse bone marrow-derived macrophages (BMDMs; IC50 = 7.5 nM), as well as cytosolic LPS-induced IL-1β release in Pam3CSK4-primed mouse BMDMs at 0.1 and 1 µM, indicating inhibition of both canonical and non-canonical NLRP3 inflammasome activation, respectively. MCC950 is selective for NLRP3 over NLRC4 and absent in melanoma 2 (AIM2) inflammasomes and does not inhibit LPS-induced NLRP3 priming in mouse BMDMs at 10 µM. It reduces ox-LDL-induced increases in caspase-1 activity and inhibits pyroptosis in THP-1 macrophages when used at a concentration of 1 µM. MCC950 (10 mg/kg) reduces myocardial fibrosis in mice following myocardial infarction induced by left coronary artery ligation. It improves forelimb grip strength and reduces spinal edema in a mouse model of spinal crush injury at the same dose.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.